Get the Stockscreener App
17.06
2.64%
-0.34
After Hours:
17.10
0.04
+0.23%
Mediwound Ltd stock is traded at $17.06, with a volume of 38,076.
It is down -2.64% in the last 24 hours and down -1.05% over the past month.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
See More
Previous Close:
$17.40
Open:
$17.37
24h Volume:
38,076
Relative Volume:
0.40
Market Cap:
$219.15M
Revenue:
$16.96M
Net Income/Loss:
$-23.88M
P/E Ratio:
-8.1354
EPS:
-2.097
Net Cash Flow:
$-20.66M
1W Performance:
-1.63%
1M Performance:
-1.05%
6M Performance:
-1.80%
1Y Performance:
-12.09%
1-Day Range:
$16.96
$17.54
1-Week Range:
$16.46
$17.59
52-Week Range:
$14.14
$22.50
Mediwound Ltd Stock (MDWD) Company Profile
Compare MDWD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDWD
Mediwound Ltd
|
17.06 | 222.62M | 16.96M | -23.88M | -20.66M | -2.097 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.64 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.11 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.36 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.80 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.29 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mediwound Ltd Stock (MDWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-02-25 | Initiated | Alliance Global Partners | Buy |
| Feb-28-25 | Initiated | Craig Hallum | Buy |
| Jul-16-24 | Reiterated | Maxim Group | Buy |
| Dec-22-22 | Initiated | Maxim Group | Buy |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Sep-23-20 | Initiated | BTIG Research | Buy |
| Nov-28-16 | Initiated | Aegis Capital | Buy |
| Aug-17-16 | Initiated | Wells Fargo | Outperform |
| Apr-16-14 | Initiated | Oppenheimer | Outperform |
View All
Mediwound Ltd Stock (MDWD) Latest News
MediWound Ltd. (NASDAQ:MDWD) Q4 2025 earnings call transcript - MSN
MediWound (MDWD) Stock Price, News & Analysis - MarketBeat
Medical Maggots Market Hits New High | Major Giants BioMonde, Maggot Therapy, MediWound - openPR.com
Menora Mivtachim Holdings LTD. Purchases 61,039 Shares of MediWound Ltd. $MDWD - MarketBeat
Rosalind Advisors Inc. Buys 341,993 Shares of MediWound Ltd. $MDWD - MarketBeat
Performance Recap: Is MediWound Ltd forming a bullish divergenceDip Buying & AI Optimized Trading Strategy Guides - baoquankhu1.vn
FY2030 Earnings Estimate for MediWound Issued By Maxim Group - Defense World
Institution Moves: Does MediWound Ltd meet Warren Buffetts criteria2026 Earnings Impact & Advanced Swing Trade Entry Plans - baoquankhu1.vn
FY2030 Earnings Forecast for MediWound Issued By Maxim Group - MarketBeat
MediWound Is the Biotech Governments Have Been Stockpiling for E - GuruFocus
MediWound Is the Biotech Governments Have Been Stockpiling for Exactly These Kinds of Wars (NASDAQ: MDWD) - TipRanks
MediWound outlines $24M–$26M 2026 revenue target while expanding EscharEx clinical programs - MSN
MediWound (MDWD) Q4 2025 Earnings Call Transcript - AOL.com
MDWD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MediWound Ltd. (NASDAQ:MDWD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Behavioral Patterns of MDWD and Institutional Flows - Stock Traders Daily
MediWound (NASDAQ:MDWD) Stock Rating Lowered by Wall Street Zen - MarketBeat
MediWound Ltd. (NASDAQ:MDWD) Q4 2025 Earnings Call Transcript - Insider Monkey
MediWound: Q4 Earnings Snapshot - theheraldreview.com
Mediwound earnings beat by $0.03, revenue fell short of estimates - Investing.com Australia
MediWound Q4 Earnings Call Highlights - MarketBeat
MediWound (MDWD) Heavy FY 2025 Losses Test High Growth And Premium P/S Narrative - simplywall.st
MediWound Q4 2025 Earnings Call Transcript - MarketBeat
MediWound Files Annual Report on Form 20-F - Bluefield Daily Telegraph
MediWound Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
MediWound (NASDAQ:MDWD) Issues Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
MDWD: Expanded manufacturing, clinical progress, and strong guidance despite 2025 revenue decline - TradingView
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
MDWD Maintains Revenue Forecasts Through 2028 - GuruFocus
MediWound (MDWD) Reports Lower-than-Expected Q4 Revenue - GuruFocus
MediWound: Overview of Fourth Quarter Financial Results - Bitget
MEDIWOUND ($MDWD) Releases Q4 2025 Earnings - Quiver Quantitative
MediWound Posts 2025 Loss but Strengthens Cash and Advances EscharEx, NexoBrid Capacity - TipRanks
MediWound (NASDAQ: MDWD) posts 2025 loss with cash rising above $53M - Stock Titan
Insights into MediWound Q4 Earnings - Benzinga
MediWound Ltd. recently announced that it has once again confirmed its financial forecast targets for the coming years. - Bitget
What to Expect from MediWound's Earnings - Benzinga
Earnings Preview: MediWound to Report Financial Results Pre-market on March 05 - 富途牛牛
Mediwound Ltd expected to post a loss of 63 cents a shareEarnings Preview - TradingView
MediWound at TD Cowen Conference: Strategic Growth and Market Expansion - Investing.com Australia
MediWound Updates NexoBrid Growth, EscharEx Phase III Timeline and BARDA Talks at Oppenheimer Conference - MarketBeat
Clal Insurance Enterprises Holdings Ltd Acquires New Position in MediWound Ltd. $MDWD - MarketBeat
MediWound at Oppenheimer Conference: Strategic Growth and Innovation - Investing.com Australia
MediWound (MDWD) Expected to Announce Earnings on Thursday - MarketBeat
(MDWD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
MediWound (NASDAQ:MDWD) Share Price Passes Below 200-Day Moving AverageTime to Sell? - MarketBeat
Will MediWound Ltd. stock benefit from green energy trendsEarnings Summary Report & Safe Swing Trade Setups - mfd.ru
MediWound Shareholders Approve Expansion of 2024 Equity Incentive Pool - The Globe and Mail
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results - Bitget
Mediwound Ltd Stock (MDWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):